{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:41:22Z","timestamp":1771519282825,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejphar.2020.173717","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:55:19Z","timestamp":1604346919000},"page":"173717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead"],"prefix":"10.1016","volume":"890","author":[{"given":"Harmanjit","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prerna","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Kumar","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejphar.2020.173717_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.ejphar.2020.173717_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","article-title":"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","volume":"97","author":"Arshad","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173717_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173717_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173717_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173717_bib8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173717_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4103\/ijmr.IJMR_2234_20","article-title":"Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19","volume":"151","author":"Chatterjee","year":"2020","journal-title":"Indian J. Med. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173717_bib10","first-page":"215","article-title":"A pilot study of HCQS in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen","year":"2020","journal-title":"J. Zhejiang Univ."},{"key":"10.1016\/j.ejphar.2020.173717_bib11","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"MedRxiv, 2020"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173717_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib13","unstructured":"Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. FDA; FDA. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and."},{"key":"10.1016\/j.ejphar.2020.173717_bib14","series-title":"Interim Guidance on Management Pending Empirical Evidence","author":"Covid\u201019","year":"2020"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173717_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/mp050043s","article-title":"A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict","volume":"2","author":"Duvvuri","year":"2005","journal-title":"Mol. Pharm."},{"issue":"10240","key":"10.1016\/j.ejphar.2020.173717_bib17","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S0140-6736(20)31290-3","article-title":"Expression of concern: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"395","author":"Editors","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173717_bib18","author":"FDA"},{"key":"10.1016\/j.ejphar.2020.173717_bib19","series-title":"FDA Cautions against Use of Hydroxychloroquine or Chloroquine for COVID-19 outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems","author":"FDA","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173717_bib20","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173717_bib21","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173717_bib22","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"issue":"25","key":"10.1016\/j.ejphar.2020.173717_bib23","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib25","author":"Hinton"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173717_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"10223","key":"10.1016\/j.ejphar.2020.173717_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173717_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0853-0","article-title":"Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus","volume":"26","author":"Jakhar","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib32","doi-asserted-by":"crossref","first-page":"m1198","DOI":"10.1136\/bmj.m1198","article-title":"Covid-19: risk factors for severe disease and death","volume":"368","author":"Jordan","year":"2020","journal-title":"BMJ, 368"},{"issue":"11","key":"10.1016\/j.ejphar.2020.173717_bib33","first-page":"e698","article-title":"Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study","volume":"2","author":"Lane","year":"2020","journal-title":"MedRxiv, 2020"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173717_bib34","doi-asserted-by":"crossref","first-page":"105988","DOI":"10.1016\/j.ijantimicag.2020.105988","article-title":"Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?","volume":"55","author":"Lee","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173717_bib35","article-title":"Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence","volume":"369","author":"Lenzer","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2020.173717_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.ejphar.2020.173717_bib37","series-title":"The Pipeline","article-title":"The politics of hydroxychloroquine","author":"Lowe","year":"2020"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173717_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Bioscience Trends"},{"key":"10.1016\/j.ejphar.2020.173717_bib39","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","author":"Magagnoli","year":"2020","journal-title":"Med. Plus"},{"key":"10.1016\/j.ejphar.2020.173717_bib40","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ejphar.2020.173717_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.35.4.569","article-title":"Fulminant hepatic failure secondary to hydroxychloroquine","volume":"35","author":"Makin","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2020.173717_bib42","author":"Management of Covid-19"},{"key":"10.1016\/j.ejphar.2020.173717_bib43","article-title":"RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.ejphar.2020.173717_bib44","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","article-title":"Retraction\u2014hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"395","author":"Mehra","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejphar.2020.173717_bib45","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.ejphar.2020.173717_bib46","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","author":"Million","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173717_bib47","author":"Ministry of Health and Family Welfare"},{"key":"10.1016\/j.ejphar.2020.173717_bib48","series-title":"Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial","author":"Mitj\u00e0","year":"2020"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173717_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.23296","article-title":"Examination of hydroxychloroquine use and hemolytic anemia in g6pdh-deficient patients","volume":"70","author":"Mohammad","year":"2018","journal-title":"Arthritis Care Res."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173717_bib50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med. Maladies Infect."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173717_bib51","first-page":"185","volume":"43","year":"2020","journal-title":"Zhonghua Jiehe He Huxi Zazhi"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173717_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2230.2001.00857-3.x","article-title":"Fatal toxic epidermal necrolysis associated with hydroxychloroquine","volume":"26","author":"Murphy","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173717_bib53","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2020.8543","article-title":"National institute for the infectious diseases \u201cL. Spallanzani\u201d, IRCCS. Recommendations for COVID-19 clinical management","volume":"12","author":"Nicastri","year":"2020","journal-title":"Infect. Dis. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173717_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030623","article-title":"Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review","volume":"9","author":"Pang","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib55","unstructured":"Plaquenil\u00ae. Hydroxychloroquine Sulfate Tablets, USP. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009768s037s045s047lbl.pdf. ((n.d.))."},{"key":"10.1016\/j.ejphar.2020.173717_bib56","author":"President\u2019s tweet","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173717_bib57","author":"Retraction Watch"},{"issue":"24","key":"10.1016\/j.ejphar.2020.173717_bib59","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2020.173717_bib61","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID\u201019","volume":"4","author":"Singh","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173717_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.173717_bib63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ejphar.2020.173717_bib66","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173717_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173717_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173717_bib69","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.25689","article-title":"Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China","volume":"92","author":"Wang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173717_bib70","author":"WHO"},{"key":"10.1016\/j.ejphar.2020.173717_bib71","unstructured":"WHO. Coronavirus disease (COVID-19) weekly epidemiological update 31st August 2020. (Accessed 15 September 2020)."},{"key":"10.1016\/j.ejphar.2020.173717_bib72","series-title":"halts Trial of Hydroxychloroquine in COVID-19 Patients","author":"WHO","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173717_bib73","series-title":"Resumes Study of Hydroxychloroquine for Treating COVID-19","author":"WHO","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173717_bib74","series-title":"Suspends Hydroxychloroquine Study over Safety Concerns","author":"WHO","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173717_bib75","series-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020"},{"issue":"11","key":"10.1016\/j.ejphar.2020.173717_bib76","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/M20-1334","article-title":"Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know","volume":"172","author":"Yazdany","year":"2020","journal-title":"Ann. Intern. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920308098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920308098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:45:27Z","timestamp":1757976327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920308098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":66,"alternative-id":["S0014299920308098"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173717","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173717"}}